Teijin To Partner With Amgen For Autoimmune Blockbuster Drugs
This article was originally published in PharmAsia News
Executive Summary
Teijin plans a partnership with Amgen to develop drugs for autoimmune diseases, including rheumatoid arthritis, drawing on the Japan drug maker's basic protein research.